This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO Gestione

Gestione criteri di controllo 3/4

AVROBIO Il CEO è Erik Ostrowski, nominato in Jan2019, e ha un mandato di 5.42 anni. la retribuzione annua totale è $ 1.59M, composta da 31.7% di stipendio e 68.3% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.065% delle azioni della società, per un valore di $ 41.58K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.7 anni e 6.2 anni.

Informazioni chiave

Erik Ostrowski

Amministratore delegato

US$1.6m

Compenso totale

Percentuale dello stipendio del CEO	31.7%
Mandato del CEO	5.4yrs
Proprietà del CEO	0.07%
Durata media del management	2.7yrs
Durata media del Consiglio di amministrazione	6.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Erik Ostrowski rispetto agli utili di AVROBIO?
Data	Compenso totale	Stipendio	Guadagni aziendali
Mar 31 2024	n/a	n/a	US$30m
Dec 31 2023	US$2m	US$504k	US$12m
Sep 30 2023	n/a	n/a	-US$4m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$101m
Dec 31 2022	US$1m	US$460k	-US$106m
Sep 30 2022	n/a	n/a	-US$109m
Jun 30 2022	n/a	n/a	-US$119m
Mar 31 2022	n/a	n/a	-US$122m
Dec 31 2021	US$3m	US$439k	-US$119m
Sep 30 2021	n/a	n/a	-US$119m
Jun 30 2021	n/a	n/a	-US$123m
Mar 31 2021	n/a	n/a	-US$121m
Dec 31 2020	US$2m	US$424k	-US$120m
Sep 30 2020	n/a	n/a	-US$114m
Jun 30 2020	n/a	n/a	-US$95m
Mar 31 2020	n/a	n/a	-US$82m
Dec 31 2019	US$3m	US$412k	-US$73m

Compensazione vs Mercato: La retribuzione totale di Erik ($USD 1.59M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 650.00K ).

Compensazione vs guadagni: La retribuzione di Erik è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Erik Ostrowski (52 yo)

5.4yrs

Mandato

US$1,590,892

Compensazione

Mr. Erik John Ostrowski, MBA, has been Chief Financial Officer and Treasurer at AVROBIO, Inc since January 2019 and served as its Principal Accounting Officer. He serves as President and Interim Chief Exec...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Erik Ostrowski	President	5.4yrs	US$1.59m	0.065% $ 41.6k
Azadeh Golipour	Chief Technology Officer	2.4yrs	US$1.27m	0.084% $ 53.5k
Essra Ridha	Chief Medical Officer	2.7yrs	US$1.34m	0.035% $ 22.5k
Jeffrey Medin	Scientific Founder	no data	Nessun dato	Nessun dato
Steven Avruch	Chief Legal Officer & Secretary	5.4yrs	US$1.77m	0.049% $ 31.3k
Scott Gottesman	Vice President of Human Resource	2.4yrs	Nessun dato	Nessun dato
Kirsten Dupuis	Chief of Staff	no data	Nessun dato	Nessun dato

2.7yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di AVRO è considerato esperto (durata media dell'incarico 2.7 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Ian T. Clark	Independent Director	6.4yrs	US$63.97k	0% $ 0
Phillip Donenberg	Independent Non-Employee Director	6yrs	US$72.97k	0.0044% $ 2.8k
Bruce Booth	Independent Chairman of the Board	8.3yrs	US$98.97k	0% $ 0
Philip Vickers	Independent Director	5.4yrs	US$73.97k	0.011% $ 6.8k
Gail Farfel	Director	3.7yrs	US$61.47k	0% $ 0
Annalisa Lisa Jenkins	Independent Director	6.2yrs	US$76.97k	0% $ 0
Christopher Paige	Independent Director	8.4yrs	US$72.97k	0.56% $ 358.6k

6.2yrs

Durata media

63yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di AVRO sono considerati esperti (durata media dell'incarico 6.2 anni).

This company is no longer active

AVROBIO Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Chief Business Officer notifies of intention to sell stock

Co- Founder exercised options to buy US$104k worth of stock.

Insufficient new directors

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

New 90-day low - US$15.85

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione